"LIMITED PROMOTION" OF UNAPPROVED DEVICES AT TRADE SHOWS
This article was originally published in The Gray Sheet
Executive Summary"LIMITED PROMOTION" OF UNAPPROVED DEVICES AT TRADE SHOWS would be allowed by FDA under the latest draft of a compliance policy guide governing promotion of devices that are pending premarket approval or 510(k) clearance, according to agency staffers. However, the policy, currently under review by FDA's Office of General Counsel, makes two stipulations regarding disclosure of product status: first, trade show displays must state prominently that the product is awaiting FDA clearance/approval and is not currently being marketed in the U.S., and second, the firm may not claim or suggest that the device is "safe and effective."
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.